Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2026 11:00 ET | Source: Institute of Molecular and Clinical Ophthalmology Basel (IOB)

What if you could reboot sick cells?

Researchers at IOB developed targeted delivery of healthy mitochondria to diseased cells, opening new paths for treating mitochondrial disorders.
April 15, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms

SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
April 15, 2026 08:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). ...
April 15, 2026 00:41 ET | Source: Revolution Medicines, Inc.

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
April 14, 2026 14:08 ET | Source: Galera Therapeutics

Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian’s pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.Obsidian’s lead...
April 14, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy

SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
April 14, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting

Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104 Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T...
April 13, 2026 16:01 ET | Source: Revolution Medicines, Inc.

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...
April 13, 2026 13:21 ET | Source: BCC Research LLC

Dermatology Devices Market to Reach $25.6 Billion by 2030, Driven by Rising Skin Cancer Incidence and Aesthetic Demand

Market growth is fueled by growing awareness of skin health, technological innovation, and expanding applications in both medical and cosmetic dermatology.
April 13, 2026 08:00 ET | Source: Revolution Medicines, Inc.

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the...